Filtered By:
Condition: Heart Attack
Infectious Disease: COVID-19
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 684 results found since Jan 2013.
COVID-19 Infected ST-Elevation Myocardial Infarction in INDIA (COSTA INDIA)
CONCLUSIONS: In this large registry of STEMI patients, we did not find significant excess in in-hospital mortality among COVID-19 co-infected patients compared with non-infected patients despite lower rate of primary PCI and reperfusion treatment, though composite of in-hospital mortality, re-infarction, stroke and heart failure was higher.PMID:37230465 | PMC:PMC10204278 | DOI:10.1016/j.ihj.2023.05.009
Source: Indian Heart J - May 25, 2023 Category: Cardiology Authors: Abdullakutty Jabir Geevar Zachariah Padinhare Purayil Mohanan Mohit Dayal Gupta Sivasubramanian Ramakrishnan Chandra Bhan Meena Sridhar L Meennahalli Palleda Girish Dipak Ranjan Das Anshul Gupta Praveen Nagula Tom Devasia Bhavesh Vajifdar None Kamlesh Tha Source Type: research
Evidence That Increasing Serum 25(OH)D Concentrations to 30 ng/mL in the Kingdom of Saudi Arabia and the United Arab Emirates Could Greatly Improve Health Outcomes
Biomedicines. 2023 Mar 23;11(4):994. doi: 10.3390/biomedicines11040994.ABSTRACTAccumulating evidence supports the potential protective effects of vitamin D against chronic diseases such as Alzheimer's disease, autoimmune diseases, cancers, cardiovascular disease (ischaemic heart disease and stroke), type 2 diabetes, hypertension, chronic kidney disease, stroke, and infectious diseases such as acute respiratory tract diseases, COVID-19, influenza, and pneumonia, as well as adverse pregnancy outcomes. The respective evidence is based on ecological and observational studies, randomized controlled trials, mechanistic studies, ...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: William B Grant Fatme Al Anouti Barbara J Boucher Hana M A Fakhoury Meis Moukayed Stefan Pilz Nasser M Al-Daghri Source Type: research
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04508023.PMID:37154020 | DOI:10.1161/CIRCULATIONAHA.123.063901
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Gregory Piazza Alex C Spyropoulos Judith Hsia Mark Goldin William J Towner Alan S Go Todd M Bull Stephen Weng Concetta Lipardi Elliot S Barnathan Marc P Bonaca PREVENT-HD Investigators Source Type: research
Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities
Conclusions COVID-19 inpatients with cardiovascular disease experience high rates of ATE, VTE, or ACM through 90 days post-discharge. Age > 75 years, PAD, CAS, CHF, previous VTE, and ICU admission are independent risk factors.PMID:37146648 | DOI:10.1055/a-2087-3003
Source: Thrombosis and Haemostasis - May 5, 2023 Category: Hematology Authors: Dimitrios Giannis Mark Goldin Husneara Rahman Cristina P Sison Martin Lesser Sam Ngu James Tsang Michael Qiu Shreya Sanghani Jackson Yeh Miltiadis Matsagkas Eleni Arnaoutoglou Alex C Spyropoulos Source Type: research
COVID-19 pandemic on coronary artery and cerebrovascular diseases in Southern Spain: interrupted time series analysis
CONCLUSIONS: A decline in AMI and CVD daily hospital admissions during the first and second wave of COVID-19 pandemic was noted. Gender differences were observed, but no clear impact was observed in percutaneous interventions.PMID:37070925 | DOI:10.26355/eurrev_202304_31955
Source: European Review for Medical and Pharmacological Sciences - April 18, 2023 Category: Drugs & Pharmacology Authors: F J Rodr íguez-Cortés J E Jim énez-Hornero J F Alcal á-Diaz R M Mi ñarro-Del Moral J L Romero-Cabrera R Manfredini M A Rodr íguez-Borrego P J L ópez-Soto Source Type: research
